One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration

British Journal of Ophthalmology

Volumn 102, Issue 1, 2018, Pages 91-96

  Braimah, Imoro Zeba ^a,b   Agarwal, Komal ^b   Mansour, Ahmad ^c,d   Chhablani, Jay ^b  

^a UNIVERSITY OF GHANA   (Ghana)

^b L V PRASAD EYE INSTITUTE   (India)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^d RAFIC HARIRI UNIVERSITY HOSPITAL   (Lebanon)

Author keywords

Aflibercept; AMD; Anti VEGF; Bevacizumab; Choroidal neovascularization; Ranibizumab; Ziv aflibercept

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; HYBRID PROTEIN; RANIBIZUMAB; VASCULOTROPIN RECEPTOR;

AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DOSE RESPONSE; DRUG TOLERANCE; FEMALE; FOLLOW UP; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; RETINA MACULA LUTEA; RETROSPECTIVE STUDY; THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMAGING, THREE-DIMENSIONAL; INTRAVITREAL INJECTIONS; MACULA LUTEA; MALE; MIDDLE AGED; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; WET MACULAR DEGENERATION;

EID: 85026291004     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2017-310318     Document Type: Article

References (27)

1. Amoaku WM, Chakravarthy U, Gale R, et al. Defining response to anti-VEGF therapies in Neovascular AMD. Eye 2015;29:721-31.
2. Eghøj MS, Sørensen TL. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 2012;96:21-3.
3. Krebs I, Glittenberg C, Ansari-Shahrezaei S, et al. Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration. Br J Ophthalmol 2013;97:1443-6.
4. Gasperini JL, Fawzi AA, Khondkaryan A, et al. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol 2012;96:14-20.
5. Nagai N, Suzuki M, Uchida A, et al. Non-responsiveness to intravitreal aflibercept treatment in neovascular age-related macular degeneration: implications of serous pigment epithelial detachment. Sci Rep 2016;6:29619.
6. Suzuki M, Nagai N, Izumi-Nagai K, et al. Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration. Br J Ophthalmol 2014;98:1186-91.
7. Singh RP, Srivastava SK, Ehlers JP, et al. A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis. Clin Ophthalmol 2015;9:1759-66.
8. Bakall B, Folk JC, Boldt HC, et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol 2013;156:15-22.
9. Chan CK, Jain A, Sadda S, et al. Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an american Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2014;112:160-98.
10. Chang AA, Broadhead GK, Hong T, et al. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration: 12-month safety and efficacy outcomes. Ophthalmic Res 2015;55:84-90.
11. Gharbiya M, Iannetti L, Parisi F, et al. Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Biomed Res Int 2014;2014:1-7.
12. Gokce G, Durukan AH, Koylu MT, et al. Efficacy of aflibercept on exudative age-related macular degeneration in patients exhibiting complete ranibizumab resistance and tachyphylaxis. Arq Bras Oftalmol 2016;79:384-9.
13. Hariri A, Diniz B, Fou LV, et al. Quantitative OCT subanalysis of eyes with choroidal neovascularization switched from multiple injections of bevacizumab or ranibizumab to intravitreal aflibercept. Ophthalmic Surg Lasers Imaging Retina 2015;46:195-200.
14. Yonekawa Y, Andreoli C, Miller JB, et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol 2013;156:29-35.
15. Chang AA, Li H, Broadhead GK, et al. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Ophthalmology 2014;121:188-92.
16. Chhablani J, Narayanan R, Mathai A, et al. Short-term safety profile of intravitreal ziv-aflibercept. Retina 2016;36:1126-31.
17. Mansour AM, Al-Ghadban SI, Yunis MH, et al. Ziv-aflibercept in macular disease. Br J Ophthalmol 2015;99:1055-9.
18. Mansour AM, Chhablani J, Antonios RS, et al. Three-month outcome of ziv-aflibercept for exudative age-related macular degeneration. Br J Ophthalmol 2016;100:1629-33.
19. Aghdam KA, Pielen A, Framme C, et al. Visual and anatomic outcomes after conversion to aflibercept in neovascular age-related macular degeneration: 12-month results. Eur J Ophthalmol 2016;26:473-8.
20. Ho VY, Yeh S, Olsen TW, et al. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Ophthalmol 2013;156:23-8.
21. Pfau M, Fassnacht-Riederle HM, Freiberg FJ, et al. [Switching Therapy from Ranibizumab and/or Bevacizumab to Aflibercept in Neovascular Age-Related Macular Degeneration (AMD): One-Year Results]. Klin Monbl Augenheilkd 2016;233:945-50.
22. Seguin-Greenstein S, Lightman S, Tomkins-Netzer O. A Meta-analysis of studies evaluating visual and anatomical outcomes in patients with treatment resistant neovascular Age-Related Macular Degeneration following switching to treatment with aflibercept. J Ophthalmol 2016;2016:4095852.
23. Hatz K, Prünte C. Intravitreal aflibercept in neovascular age-related macular degeneration with limited response to ranibizumab: a treat-and-extend trial. Retina 2017;37:1185-92.
24. Broadhead GK, Hong T, Zhu M, et al. Response of pigment epithelial detachments to intravitreal aflibercept among patients with treatment-resistant neovascular agerelated macular degeneration. Retina 2015;35:975-81.
25. Kanesa-Thasan A, Grewal DS, Gill MK, et al. Quantification of change in pigment epithelial detachment volume and morphology after transition to Intravitreal Aflibercept in eyes with recalcitrant neovascular AMD: 18-month results. Ophthalmic Surg Lasers Imaging Retina 2015;46:638-41.
26. Patel KH, Chow CC, Rathod R, et al. Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab. Eye 2013;27:663-8.
27. Chin-Yee D, Eck T, Fowler S, et al. A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. Br J Ophthalmol 2016;100.